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EDITORIALThe Journal of Thoracic Oncology in the Next DecadeAlex A. Adjei, MD, PhDStarting with this issue, Elsevier is the new publisher
of the Journal of Thoracic Oncology (JTO). This change
in publisher also signiﬁes a move by the International
Association for the Study of Lung Cancer and the
editorial team to signiﬁcantly enhance the stature
of the JTO as the premier journal for thoracic
malignancies.
We want the JTO to be where readers turn for the
most up to date and authoritative information on
thoracic malignancies. This editorial outlines new fea-
tures that will be in place with the move to Elsevier. A
subsequent publication will address updated criteria for
the acceptance of manuscripts for publication in the JTO.
One feature that Elsevier provides for authors is a
Share Link to their newly published articles on Sci-
enceDirect. The link provides 50 days of free access to
the article—after that period, the usual access rules
apply. Users clicking on the Share Link within the 50-
day period will be taken directly to the article with no
sign-up or registration required. Share Links are ideal
for sharing via email and social networks, such as
Facebook, Twitter, LinkedIn, and ResearchGate. Au-
thors will automatically receive the Share Link at the
ﬁnal citable publication stage of the article. If several
authors are listed, the corresponding author will
receive the Share Link, which can then be shared with
coauthors.Journal of Thoracic Oncology Vol. 11 No. 1: 8Articles will be added to Scopus, the world’s largest
abstract and citation database of peer-reviewed
literature.
Prompt publication of accepted manuscripts will
occur. A ﬁnal revised manuscript will be posted on-line
within two weeks of acceptance. After the author ap-
proves proofs, the typeset proof will be immediately
posted.
Authors canmonitor the impact of theirworkwith “My
Research Dashboard,” which provides real time feedback
on how publications are being downloaded, shared, and
cited. Authors can also track and analyze the on-line ac-
tivity around their articles with Altmetrics data.
Audio slide presentations will allow authors to
explain their paper in their own words. These are short,
webcast-style presentations that will be shown next to
the online article on ScienceDirect. This format gives
authors the opportunity to directly present their
research and help readers quickly understand what a
paper is about and appreciate its relevance.
The JTO app will be discontinued. JTO will be acces-
sible on tablets and other handheld devices through
responsive web design. A full PDF version of JTO will be
available for access in areas without Wi-Fi connectivity.
The journal cover and internal layout have both been
updated. Editorial Manager will still be the portal
through which articles will be submitted.Roswell Park Cancer Institute, Buffalo, New York
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